p*e
2 楼
I am not sure...
p*e
4 楼
周末刚刚被某娱乐周刊评为2014的潜力股
2014 Top health-care stock No. 1: Joining the pack
It's a heck of a lot easier to determine the potential value a biotech when
there's a company further ahead with nearly identical assets. Orexigen (
NASDAQ: OREX ) has two.
The biotech is developing an obesity drug Contrave, which will be reviewed
by the FDA in 2014. Further ahead, Arena Pharmaceuticals (NASDAQ: ARNA )
developed obesity drug Belviq that launched this year. VIVUS (NASDAQ: VVUS
) sells Qsymia, which has been on the market for a little over a year.
Without an approval in hand, investors are rightfully discounting Orexigen.
Or put another way, Orexigen should have a similar value to Arena
Pharmaceuticals and VIVUS once investors are convinced that it has the same
potential as the other two.
An approval of Contrave looks highly likely after Orexigen successfully
completed all the FDA's requests from an earlier rejection. Orexigen has the
potential to double in value next year, which could make it one of 2014's
top health-care stocks.
【在 j********2 的大作中提到】
: RT
2014 Top health-care stock No. 1: Joining the pack
It's a heck of a lot easier to determine the potential value a biotech when
there's a company further ahead with nearly identical assets. Orexigen (
NASDAQ: OREX ) has two.
The biotech is developing an obesity drug Contrave, which will be reviewed
by the FDA in 2014. Further ahead, Arena Pharmaceuticals (NASDAQ: ARNA )
developed obesity drug Belviq that launched this year. VIVUS (NASDAQ: VVUS
) sells Qsymia, which has been on the market for a little over a year.
Without an approval in hand, investors are rightfully discounting Orexigen.
Or put another way, Orexigen should have a similar value to Arena
Pharmaceuticals and VIVUS once investors are convinced that it has the same
potential as the other two.
An approval of Contrave looks highly likely after Orexigen successfully
completed all the FDA's requests from an earlier rejection. Orexigen has the
potential to double in value next year, which could make it one of 2014's
top health-care stocks.
【在 j********2 的大作中提到】
: RT
c*o
5 楼
青龙老师说点评下。
相关阅读
FUQI has bottomedwho moved our cheeseAONE 新低蓉儿,蓉儿,~~~~~~~~~~~~~~~~~~~~BROKER要是倒闭了怎么办呢?转过来一个岗位招聘信息,不知股版同仁看过没?T/VZ (转载)pnx果然是保险里面最烂的阿SHORT了CALL,怎么突然给了那么多SHORT的股票report from frontline: UNG OKBOSTON征男友(附照片) (转载)靠,刚买的QID也入水了...I did not achieve my goal when US market is on,今天还会有夜半鸡叫吗?这个版最有价值的东西又被破坏了!同学们,上船了LOng Or shOrt frOm here?你们这帮人,怎么都是不务正业啊?RIM 又要加烧了!求助:有免费的看实时股价的软件吗?